Cognition Therapeutics (CGTX): Price and Financial Metrics

Cognition Therapeutics (CGTX): $0.30

0.02 (-7.55%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add CGTX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#213 of 332

in industry

CGTX Price/Volume Stats

Current price $0.30 52-week high $2.54
Prev. close $0.32 52-week low $0.22
Day low $0.30 Volume 1,264,800
Day high $0.34 Avg. volume 1,392,875
50-day MA $0.33 Dividend yield N/A
200-day MA $0.48 Market Cap 18.60M

CGTX Stock Price Chart Interactive Chart >


Cognition Therapeutics (CGTX) Company Bio


Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.


CGTX Latest News Stream


Event/Time News Detail
Loading, please wait...

CGTX Latest Social Stream


Loading social stream, please wait...

View Full CGTX Social Stream

CGTX Price Returns

1-mo 20.68%
3-mo -27.83%
6-mo -60.00%
1-year -81.93%
3-year -86.11%
5-year N/A
YTD -57.22%
2024 -62.09%
2023 -11.90%
2022 -66.77%
2021 N/A
2020 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!